Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

48.19USD
19 Oct 2018
Change (% chg)

$-1.37 (-2.76%)
Prev Close
$49.56
Open
$49.65
Day's High
$51.23
Day's Low
$48.13
Volume
643,193
Avg. Vol
969,038
52-wk High
$111.36
52-wk Low
$22.93

Select another date:

Mon, Jun 4 2018

Mixed results for Bristol/Nektar combination in cancer trial

Chicago, June 3 Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million

* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

Select another date: